gene_symbol
FCGR2A
hgnc_id
HGNC:3616
binding_type
receptor ligand recognition
cytotoxicity
NO
cytotoxicity_type
INDIRECT
cytotoxicity_mechanism
Zolbetuximab binds CLDN18.2 on tumor cells; its Fc engages Fc gamma receptor IIa (CD32A) on immune effector cells to trigger ADCC/ADCP and complement-mediated killing of CLDN18.2+ cells. FcγRIIa-expressing cells are not targeted or killed.
enzyme_product
Off
epitope
Off
variant
Off
isoform
Off
hla_specific
Off
gated
Off
other_modifier
Fc-dependent engagement mediating antibody-dependent cellular phagocytosis (ADCP)
trial_id_tar_ref
drug_id_tar_ref
disease_id_tar_ref
nct_id_tar_ref
NCT06767449
disease_id_num_tar_ref
2442
drug_id_num_tar_ref
6530